Key Events This Week
Mar 9: New 52-week low (Rs.573.45)
Mar 10: Partial recovery to Rs.604.75 (+4.09%)
Mar 11-13: Consecutive declines ending at Rs.577.55 (-0.31% on last day)
Weekly Summary: Stock closed down 7.85% vs Sensex down 4.87%
Apr 09
BSE+NSE Vol: 1.02 lacs

Supriya Lifescience Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its technical outlook deteriorate from mildly bearish to bearish, reflecting a shift in price momentum and mixed signals from key technical indicators. Despite a modest weekly price gain, the stock’s overall trend and momentum indicators suggest caution for investors amid a challenging market environment.
Read full news article
Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
The Sensex gained 2.49% on 1 Apr 2026, yet Supriya Lifescience Ltd outpaced the broader market with a 7.35% rally, reaching an intraday high of Rs 622. This 5.28-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector's 2.07% gain highlights a stock-specific momentum shift rather than a mere market tailwind.
Read full news article
Despite a broader market rally, Supriya Lifescience Ltd has slipped to a fresh 52-week low of Rs 545.65 on 24 Mar 2026, extending a recent downtrend that has seen the stock lose nearly 6% over two sessions. This decline contrasts sharply with the Sensex's modest gains and highlights stock-specific pressures weighing on the pharmaceutical company.
Read full news article
Supriya Lifescience Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
A sharp decline of 4.28% today dragged Supriya Lifescience Ltd to a fresh 52-week low of Rs 558.5, extending a downward trajectory that has seen the stock underperform the broader market significantly over the past year.
Read full news article
Supriya Lifescience Ltd’s stock declined to a fresh 52-week low of Rs.565 today, marking a continuation of its recent downward trajectory. The pharmaceutical and biotechnology company’s shares have underperformed over the past year, reflecting a combination of valuation concerns and subdued growth metrics.
Read full news article